Some plans may require prior authorization, necessitating proof of medical necessity from a healthcare provider
GLP-1 medications are typically administered once weekly via a subcutaneous injection, meaning a small injection just beneath the skin that causes minimal discomfort compared to intramuscular injections
With average results of 14.9% body weight loss over 68 weeks and nearly 70% of people achieving 10% or greater weight loss, it represents one of the most effective weight management medications available
Anyone using the bridge benefit should also discuss long-term planning with their clinician, including what happens if coverage does not extend beyond the demonstration period
GLP-1 RAs have demonstrated favorable trends toward improving endocrine and metabolic outcomes, including reductions in ALT, AST, HbA1c, body weight, BMI, LFC, and IHA
Clinical trials have shown that many patients lose between 10 to 15%, or even more, of their starting body weight over 68 weeks